Although it is largely recognized that sarcomas express several pro-angiogenic therapeutic targets, only a few trials with anti-VEGF inhibitors have been published in pediatric sarcomas mainly using bevacizumab (21–24). The gene discussed is VEGFA; the disease is sarcoma.